MAI Capital Management Sells 294,460 Shares of Autolus Therapeutics PLC Sponsored ADR $AUTL

Key Points

• MAI Capital Management significantly reduced its holdings in Autolus Therapeutics by 89.7%, owning only 33,866 shares after selling 294,460 shares.
• Autolus Therapeutics reported its quarterly earnings, achieving an EPS of ($0.18), which exceeded analysts' expectations of ($0.24).
• Wall Street analysts maintain a consensus rating of "Buy" for AUTL, with an average target price of $9.12, despite Wells Fargo lowering its price objective from $6.00 to $5.00.

MAI Capital Management lowered its stake in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) by 89.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,866 shares of the company's stock after selling 294,460 shares during the period. MAI Capital Management's holdings in Autolus Therapeutics were worth $52,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new stake in Autolus Therapeutics in the fourth quarter valued at approximately $26,000. Barclays PLC raised its stake in shares of Autolus Therapeutics by 1,094.3% during the fourth quarter. Barclays PLC now owns 11,859 shares of the company's stock valued at $28,000 after acquiring an additional 10,866 shares during the last quarter. Invesco Ltd. raised its stake in shares of Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company's stock valued at $51,000 after acquiring an additional 11,381 shares during the last quarter. OMERS ADMINISTRATION Corp bought a new position in shares of Autolus Therapeutics during the fourth quarter valued at $85,000. Finally, Exchange Traded Concepts LLC raised its stake in shares of Autolus Therapeutics by 67.2% during the first quarter. Exchange Traded Concepts LLC now owns 69,993 shares of the company's stock valued at $108,000 after acquiring an additional 28,127 shares during the last quarter. Institutional investors and hedge funds own 72.83% of the company's stock.

Wall Street Analysts Forecast Growth

AUTL has been the subject of several analyst reports. Wall Street Zen raised shares of Autolus Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Wells Fargo & Company dropped their price target on shares of Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating for the company in a research note on Wednesday, August 13th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, July 21st. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $9.12.

Autolus Therapeutics Price Performance

NASDAQ AUTL traded down $0.05 during mid-day trading on Friday, reaching $1.38. 5,526,337 shares of the stock were exchanged, compared to its average volume of 4,360,685. Autolus Therapeutics PLC Sponsored ADR has a one year low of $1.11 and a one year high of $5.00. The stock has a 50 day simple moving average of $2.05 and a 200-day simple moving average of $1.83. The stock has a market cap of $367.27 million, a P/E ratio of -1.64 and a beta of 1.87.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.06. The firm had revenue of $13.50 million for the quarter, compared to the consensus estimate of $12.92 million. Sell-side analysts anticipate that Autolus Therapeutics PLC Sponsored ADR will post -0.94 EPS for the current fiscal year.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.